ImmunoGen, Inc.  

(Public, NASDAQ:IMGN)   Watch this stock  
Find more results for IMGN
+0.16 (1.50%)
Real-time:   2:42PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.86 - 11.20
52 week 10.28 - 18.22
Open 11.06
Vol / Avg. 264,730.00/734,769.00
Mkt cap 999.47M
P/E     -
Div/yield     -
EPS -0.83
Shares 85.91M
Beta 2.07
Inst. own 89%
Oct 23, 2014
Q1 2015 Immunogen Inc Earnings Release (Estimated) - 6:30AM EDT - Add to calendar
Sep 8, 2014
Immunogen Inc at Morgan Stanley Healthcare Conference
Sep 3, 2014
Immunogen Inc at Citi Biotech Conference
Aug 13, 2014
Immunogen Inc at Canaccord Genuity Growth Conference
Aug 7, 2014
Immunogen Inc at UBS Biotech Summer 1x1 Conference
Aug 1, 2014
Q4 2014 Immunogen Inc Earnings Call
Aug 1, 2014
Q4 2014 ImmunoGen, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -461.41% -119.15%
Operating margin -461.43% -119.43%
EBITD margin - -111.75%
Return on average assets -60.39% -37.67%
Return on average equity -122.43% -72.25%
Employees 307 -
CDP Score - -


United States - Map
+1-781-8950600 (Phone)
+1-781-8950611 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company�s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The Company's TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.

Officers and directors

Stephen C. McCluski Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Daniel M. Junius President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
David B. Johnston Chief Financial Officer, Executive Vice President, Principal Financial Officer, Principal Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Ellie Harrison Chief Human Resource Officer, Vice President
Bio & Compensation  - Reuters
John M. Lambert Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 62
Bio & Compensation  - Reuters
Charles Q. Morris Executive Vice President, Chief Development Officer
Age: 48
Bio & Compensation  - Reuters
Sandra E. Poole Senior Vice President - Technical Operations.
Bio & Compensation  - Reuters
Craig Barrows Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Eric Guempel Vice President - Product Strategy and Program Management
Bio & Compensation  - Reuters
James J. O'Leary M.D. Vice President, Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters